Erlotinib Active Not Recruiting Phase 3 Trials for Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02296125AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer